Despite a significant drop in its share price since its market debut, Cerebras Systems (CBRS.US) has received a wave of bullish coverage from major Wall Street firms. The stock, often seen as a challenger to NVIDIA (NVDA), rose 3.02% to around $207 in early trading on June 8, marking a second consecutive day of modest recovery.
Nevertheless, the stock remains down nearly 42% from its first-day intraday high of $350, reached about a month ago. Its market capitalization has fallen from a peak exceeding $100 billion to approximately $44.1 billion currently. This decline in the secondary market stands in stark contrast to the overwhelmingly positive sentiment from Wall Street research desks.
Wall Street's Bullish Consensus
On Monday, a host of prominent financial institutions, including Morgan Stanley, UBS, Wedbush, Rosenblatt, Mizuho, Barclays, and Needham, simultaneously initiated coverage on Cerebras. Almost uniformly, these firms assigned "Buy," "Overweight," or "Outperform" ratings, with price targets clustering in the $250 to $300 range.
The Core Investment Thesis
The collective bullishness from Wall Street is not rooted in stellar current financials but in Cerebras's unique position within the AI chip market. The company has carved out a highly specialized niche with its product architecture.
While the AI compute market is dominated by NVIDIA's GPUs, Cerebras has taken a different path. It produces the world's only commercially deployed wafer-scale processor, the Wafer Scale Engine (WSE). Technical data indicates the latest WSE-3 integrates 4 trillion transistors and 900,000 AI-optimized cores, each with 48KB of local SRAM. The entire chip boasts 44GB of on-chip SRAM and provides 21 PB/s of on-chip memory bandwidth, which is thousands of times greater than typical HBM solutions.
This architecture fundamentally eliminates the "memory wall" bottleneck. Cerebras claims its systems can process most workloads up to 15 times faster than leading GPU solutions, making them particularly suitable for latency-sensitive AI inference scenarios.
Analyst Perspectives and Rationale
Morgan Stanley (Overweight rating, $250 target) highlighted that as AI workloads increasingly shift toward inference, demand for fast, low-latency inference is growing rapidly. The firm noted Cerebras is well-positioned to capitalize on this opportunity with a substantial backlog of signed orders and committed capacity agreements for 750 megawatts.
UBS (Buy rating, $300 target) pointed out that Cerebras's WSE is the world's largest compute chip and outperforms GPUs in certain fast-inference applications for the high-end inference market. The analyst emphasized the company's strong commercial momentum, noting it is the sole supplier providing hardware to OpenAI on a prepayment basis and is deepening its collaboration with Amazon in inference.
Wedbush (Outperform rating, $270 target) focused on the market cycle shift, stating Cerebras entered the public market just as the AI compute cycle is transitioning from training to inference. In this phase, speed, not raw FLOPS, determines the commercial value of the output. The firm views Cerebras's WSE-3, designed for fast token generation, as providing asymmetric upside potential.
Needham (Buy rating, $300 target) underscored the WSE's SRAM capacity and memory bandwidth, which are orders of magnitude greater than any other AI processor. The analyst cited the multi-billion-dollar compute agreement with OpenAI and the potential for significant upside if OpenAI exercises options for additional capacity or if Amazon deploys a substantial number of systems.
Barclays (Overweight rating, $280 target) noted Cerebras's recent agreements with OpenAI and Amazon represent significant developments in an AI chip market where customers are scrambling for limited supply. The bank positioned Cerebras in the fast-inference market, which it believes could reach a $300 billion addressable market by the end of the decade.
Mizuho (Outperform rating, $300 target) stated Cerebras is a direct beneficiary of AI capital expenditure growth. The firm expects Cerebras to lead in the fastest-growing segment, fast inference, which it forecasts will grow at a ~291% CAGR to around $550 billion by 2030. Mizuho's $300 price target is based on a 15x multiple of projected 2028 sales.
Prior to this wave of reports, Bank of America projected that Cerebras would lead all major AI chip companies with an explosive 370% earnings growth rate over the next year, a forecast that even exceeds NVIDIA's projected 195% revenue growth for the same period.
Comments